このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CMO Letter to Reduce Unnecessary Antibiotic Prescribing and Broad Spectrum Prescribing Winter 2018-9 (CMO2018-9)

2020年3月2日 更新者:Public Health England

A Randomized Controlled Trial of Behaviourally Informed Feedback Letters Sent by the Chief Medical Officer on the Amount of Antibiotics and the Percentage of Broad Spectrum Antibiotics Prescribed in Primary Care

This trial aims to reduce unnecessary prescription of antibiotics and broad spectrum antibiotics by general practitioners (GPs) in England. Unnecessary prescriptions are defined as those that do not improve patient health outcomes. The intervention is to send GPs a letter from the Chief Medical Officer (CMO) that gives feedback on their practice's prescribing levels. Specifically the sample was GPs whose practices whose prescribed more than 1.161 items per STAR-PU or whose practices prescribed more that .965 items per STAR-PU and greater than 10% broad spectrum items. The intervention groups received a letter telling them they are among the highest prescribers of either their total or broad spectrum antibiotics, with a graph showing their prescribing compared to average prescribing ("their peers"). The letter also contained a leaflet to help GPs discuss self-care advice with patients and some advice to use delayed prescriptions. The investigators hypothesize that the antibiotic prescribing rate in will be lower for the treatment group compared to the control group, following the receipt of the letter.

調査の概要

研究の種類

介入

入学 (実際)

7000

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • London、イギリス、SE1
        • Public Health England

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • GP practices that prescribed more than 1.161 Antibacterial Items/STAR-PU for the twelve months (June 2017 - May 2018)
  • GP practices that prescribed more than 0.965 Antibacterial Items/STAR-PU and also more than 10% broad spectrum items for the twelve months (June 2017 - May 2018).

Exclusion Criteria:

  • none

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:high total and high broad spectrum prescribing letter
social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
アクティブコンパレータ:high total and high broad spectrum prescribing control
standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
social norm feedback letter used as standard practice, without specific information about the prescribing percentile
実験的:high total prescribing only intervention letter
social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
アクティブコンパレータ:high total prescribing control letter
standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
social norm feedback letter used as standard practice, without specific information about the prescribing percentile
実験的:moderate total prescribing and high broad spectrum letter
social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
介入なし:moderate total prescribing and high broad spectrum control
GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
total antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU) in November for each GP practice
時間枠:1 month
antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU)
1 month
total broad spectrum antibiotic prescribing weighted by STAR-PU in November for each GP practice
時間枠:1 month
broad spectrum antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU)
1 month
percentage broad spectrum antibiotic prescribing in November for each GP practice
時間枠:1 month
percentage broad spectrum antibiotic prescribing
1 month
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in November for each GP practice
時間枠:1 month
total overall antibiotic prescribing minus total broad spectrum antibiotic prescribing
1 month
total antibiotic prescribing weighted by STAR-PU in December for each GP practice
時間枠:2 months
antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU)
2 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in December for each GP practice
時間枠:2 months
2 months
percentage broad spectrum antibiotic prescribing in December for each GP practice
時間枠:2 months
2 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in December for each GP practice
時間枠:2 months
2 months
total antibiotic prescribing in January weighted by STAR-PU for each GP practice
時間枠:3 months
3 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in January for each GP practice
時間枠:3 months
3 months
percentage broad spectrum antibiotic prescribing in January for each GP practice
時間枠:3 months
3 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in January for each GP practice
時間枠:3 months
3 months
total antibiotic prescribing weighted by STAR-PU in February for each GP practice
時間枠:4 months
4 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in February for each GP practice
時間枠:4 months
4 months
percentage broad spectrum antibiotic prescribing in February for each GP practice
時間枠:4 months
4 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in February for each GP practice
時間枠:4 months
4 months
total antibiotic prescribing weighted by STAR-PU in March for each GP practice
時間枠:5 months
5 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in March for each GP practice
時間枠:5 months
5 months
percentage broad spectrum antibiotic prescribing in March for each GP practice
時間枠:5 months
5 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in March for each GP practice
時間枠:5 months
5 months
total antibiotic prescribing weighted by STAR-PU in April for each GP practice
時間枠:6 months
6 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in April for each GP practice
時間枠:6 months
6 months
percentage broad spectrum antibiotic prescribing in April for each GP practice
時間枠:6 months
6 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in April for each GP practice
時間枠:6 months
6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年11月1日

一次修了 (実際)

2019年4月30日

研究の完了 (実際)

2019年5月30日

試験登録日

最初に提出

2019年2月27日

QC基準を満たした最初の提出物

2019年3月1日

最初の投稿 (実際)

2019年3月5日

学習記録の更新

投稿された最後の更新 (実際)

2020年3月3日

QC基準を満たした最後の更新が送信されました

2020年3月2日

最終確認日

2018年12月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • R&D 193

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

処方、適応外の臨床試験

  • Washington University School of Medicine
    University of Oklahoma Medical Center; Northwestern University Chicago Illinois; Saint Luke's...
    完了
    Walled Off Pancreatic Necrosis (WON)
    アメリカ
3
購読する